Earendil Labs and WuXi Biologics Forge Strategic Alliance to Fast-Track Bispecific, Multispecific Antibodies, and ADCs
“Earendil Labs, an AI-powered innovator in next-generation biologics, has partnered with WuXi Biologics, a leading global CRDMO, to advance multiple pipeline candidates including bispecific and multispecific antibodies as well as antibody-drug conjugates (ADCs) targeting cancer, autoimmune diseases, and other serious conditions. The deal leverages WuXi’s comprehensive development and GMP manufacturing expertise to speed up timelines, … Read more